Iridex (IRIX) Non-Current Debt (2020 - 2021)

Iridex's (IRIX) quarterly Non-Current Debt came in at $312000.0 in Q2 2021, down 75.0% quarter-over-quarter from $1.2 million in Q1 2021.

Iridex (IRIX) Non-Current Debt (2020 - 2021) Analysis & Trends

Iridex's Non-Current Debt history runs 2 years deep, the most recent figure standing at $312000.0 for Q2 2021.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $312000.0 in Q2 2021; TTM through Apr 2021 was $312000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $1.2 million, changed N/A from the prior year.
Non-Current Debt declined to $312000.0 in Q2 2021 per IRIX's latest filing, from $1.2 million in the prior quarter.
Across five years, Non-Current Debt topped out at $1.2 million in Q1 2021 and bottomed at $312000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	184.32 Bn	177.02 Bn	6.27 Bn	29.64 Bn
2	Stryker	128.89 Bn	126.01 Bn	3.81 Bn	14.22 Bn
3	Medtronic	108.88 Bn	99.66 Bn	6.41 Bn	26.17 Bn
4	Boston Scientific	68.65 Bn	67.20 Bn	3.61 Bn	10.99 Bn
5	Edwards Lifesciences	47.43 Bn	43.76 Bn	1.29 Bn	598.50 Mn
6	GE HealthCare Technologies	28.48 Bn	26.19 Bn	1.98 Bn	10.13 Bn
7	Dexcom	28.45 Bn	27.33 Bn	750.30 Mn	-
8	Smith & Nephew	26.98 Bn	26.40 Bn	-	3.18 Bn
9	Koninklijke Philips	25.54 Bn	22.42 Bn	2.07 Bn	8.07 Bn
10	Iridex	15.20 Mn	10.60 Mn	4.74 Mn	-

Download Data